FENNEC PHARMACEUTICALS INC. Cash Flow Statement
FENC|12 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$27M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
FENNEC PHARMACEUTICALS INC. generated $27M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2021 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$436.0K | -$16.0M | -$23.7M | -$18.1M | -$9.9M | -$7.0M | -$2.8M | -$659.0K | -$2.2M | $1.8M | -$37.0K | -$37.0K |
| Depreciation & Amortization | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Operating Cash Flow | $27.0M | -$17.1M | -$18.1M | -$15.6M | -$7.8M | -$3.6M | -$2.1M | -$1.9M | -$1.7M | -$2.2M | -$3.0M | -$3.2M |
| Capital Expenditures | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | -$3.0M | -$3.2M |